Thomas Colatsky, Ph.D.
Practice Head, Preclinical Development
|
 |
Dr. Colatsky has more than 30 years of experience in pharmaceutical and biotechnology research. In his last position, he was Senior Vice President and Chief Scientific Officer at Icoria Inc, a Clinical Data Company, where he led multi-disciplinary teams in biomarker and drug target discovery. Prior to joining Icoria, Dr. Colatsky held executive positions in drug discovery and clinical research at Wyeth Pharmaceuticals, including Vice President, Cardiovascular and Metabolic Disorders with responsibility for discovery programs in a broad range of therapeutic areas, including atherosclerosis, congestive heart failure, thrombosis, hypertension, diabetic complications, insulin resistance, dyslipidemia, obesity, urinary incontinence, cardiac arrhythmias, inflammation and transplantation. These efforts led to 9 IND filings and 3 NDAs.
At PharmaDirections, Dr Colatsky has led preclinical development programs targeting new formulations and indications for existing drugs, life cycle management and investor due diligence projects, and the creation of strategic plans over a wide range of therapeutic areas. He has also been involved in the in-licensing of novel development stage technologies.
Dr. Colatsky also served as the first Chief Executive Officer of Argolyn Bioscience, an early stage biotechnology company focused on the design and development of novel peptide drugs and diagnostics for CNS disorders and pain. In addition, he also served as Executive Vice President and Chief Scientific Officer at Physiome Sciences, one of the first in silico biology companies developing and commercializing computational models of complex biological systems. Dr. Colatsky is author on over 60 publications, book chap-ters and invited scientific reviews, and co-inventor on 9 pharmaceutical composition of matter patents. He has been an Established Investigator of the American Heart Association and was named an AAAS Fellow in Pharmaceutical Sciences for his work on ion channel pharmacology and drug-induced QT prolongation. He has served on numerous expert panels and editorial boards, including various NIH and AHA study sections, Car-diovascular Research, Circulation Research, and Current Drugs, and is a past President of the Philadelphia Physiological Society.
|
|
